CompoAtlas

Endométix Pro

Food supplement declared in France, declaration No 2023-9-461, decision dated 8 September 2023

Endométix Pro is a food supplement declared in France. Status: declared in France, may be marketed. 1 rule of use applies to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
Laboratoires DENSMORE
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
2 gélules
Intended populations
Women
Not recommended (according to the manufacturer)
Children (under 12), Young children (aged 1 to 3), Infants (under 1 year), Taking medication, Children (under 6), Children (under 10)
Objectives stated by the manufacturer (these are not authorised claims)
Menstrual cycles

Declaration 134645, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Potentilla anserina L.Parties aériennesPoudre (de plantes séchées ou broyées)72 mg
Foeniculum vulgare Mill.FruitExtrait sec aqueux70 mg

Other active ingredients

NamePer day
Palmitoyléthanolamidenot declared
Acétylcystéinenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
Acide ptéroylmonoglutamiqueFolates (vitamine B9)1,000 µg200 µg
NicotinamideNicotinamide (vitamine B3)900 mg54 mg
Levure enrichie en séléniumSélénium255 µg50 µg
Acide L-ascorbiqueVitamine Cpas de limite (données insuffisantes)180 mg
Succinate acide de D-alpha-tocophéryleVitamine E300 mg30 mg
Citrate de zincZinc25 mg15 mg

Additives

E470b

Other ingredients

Gélule végétale

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Foeniculum vulgare Mill.
    Read the warning, when it applies and the studies cited

    BITTER FENNEL- FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).

    Sources cited by Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Condition of application: Essential oil and Tincture.

    Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).

    Sources cited by Health Canada (1)
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).

    Sources cited by Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Health Canada monograph dated 29 November 2024

    SWEET FENNEL -FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Health Canada monograph dated 29 November 2024

  • Acétylcystéine
    Read the warning, when it applies and the studies cited

    N-ACETYL-L-CYSTEINE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney stones (Fauci et al. 1998; Mårtensson et al. 1990).

    Sources cited by Health Canada (2)
    • Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DI, Hauser SL and Longo DL, editors. Harrison's Principles of Internal Medicine, 14th edition. Toronto (ON): McGraw-Hill Health Professions Division; 1998.
    • Mårtensson J, Denneberg T, Lindell Å, Textorius O. Sulfur amino acid metabolism in cystinuria : A biochemical and clinical study of patients. Kidney International 1990;37:143-149. PubMed

    Contraindications

    Do not use if you are taking antibiotics or nitroglycerin (Repchinsky 2008; Cederlund and Märdh 1993; Parry and Neu 1977; Ardissino et al. 1997).

    Sources cited by Health Canada (4)
    • Ardissino D, Merlini PA, Savonitto S, Demicheli G, Zanini P, Bertocchi F, Falcone C, Ghio S, Marinoni G, Montemartini C, Mussini A. Effect of transdermal nitroglycerin or N- acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. Journal of the American College of Cardiology 1997;29(5):941-947. PubMed Randomised trial
    • Cederlund H, Märdh PA. Antibacterial activities of non-antibiotic drugs. Journal of Antimicrobial Chemotherapy 1993;32:355-365. PubMed Review article
    • Parry MF, Neu HC. Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. Journal of Clinical Microbiology 1977;5(1);58-61.
    • Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2023. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line